E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Malignant pleural disease of all histological cell types. 50% patients in trial will have indwelling pleural catheters for management of breathlessness. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with cancer of the lining of the lung. Half of patients will have a long term tube in place, which drains fluid from around the lung to improve their breathlessness. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To examine whether zoledronic acid in the form of Zometa reduces pleural fluid production, tumour volume and improves breathlessness and quality of life in patients with a malignant pleural disease when administered in its licenced dose for administration to patients with malignancy. |
|
E.2.2 | Secondary objectives of the trial |
To establish drug concentration in pleural fluid following intravenous administration. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1/. Malignant pleural thickening with or without pleural effusion with a. malignant fluid cytology or b. malignant pleural biopsy histology or c. in the context of clinically proven cancer elsewhere with no alternative cause found for the pleural thickening or effusion
and
2/. Age > 18 years
|
|
E.4 | Principal exclusion criteria |
1/. Chemical or surgical pleurodesis in the preceding 30 days.
2/. IV bisphosphonate within the past 3 months or ongoing therapy.
3/. Ongoing dental disease requiring intervention.
4/. Significant renal failure (calculated creatinine clearance of <40ml/min)
5/. Hypocalcaemia at randomisation.
6/. Inability to give informed consent.
7/. Pregnancy or lactation.
8/. Known allergy to bisphosphonates or exipients in the intervention preparation.
9/. Life expectancy < 4 months.
10/. Current or planned chemotherapy (However patients receiving the oral chemotherapy agent, tarceva who have been on it for more than 3 months can be included).
11/. Hormone manipulation therapy initiated in the month before trial entry (however patients receiving long term hormone manipulation can be included).
12/. Haematological malignancy.
13/. Age < 18 years (no upper age limit).
14/. Severe visual impairment.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1/. Change in gadolinium uptake and washout rate on DCE-MRI
2/. Change in dyspnoea VAS score.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Over the 9 week trial period, with long term follow up in the specialist pleural clinic at Southmead Hospital |
|
E.5.2 | Secondary end point(s) |
1/. Disease progression as measured by volume of pleural thickening on CT scan
2/. Disease progression as measured by volume of pleural thickening on DCE-MRI scan.
3/. For patients with a pleurx catheter in situ, change in fluid volume production between week 2 of run in period and each week post intervention or placebo.
4/. For patients with pleurx catheter in situ, spontaneous pleurodesis rate.
5/. Change in pleural fluid and plasma VEGF-A between baseline and each aspiration following intervention or placebo (with correlation to fluid drainage in pleurx patients).
6/. Change in volume of pleural fluid on CT. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Over the 9 week trial period, with long term follow up in the specialist pleural clinic at Southmead Hospital |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
This pilot study will be complete when the last patient attends their last visit 21 days following administration of the final dose of zometa |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |